FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to experimental pharmacology and genetic technologies. Described method is as follows. In dysferlin-deficient mice B6.A/J-Dysfprmd there is a marked increase in the duration of swimming with a load after a single introduction of a preparation based on adeno-associated virus of serotype 9 in dose of 1*1012 units of virus with the DYSF gene in amount of 50 mcl in the following muscles of both hind limbs: m. vastus lateralis, m. tibialis anterior, m. gastrocnemius lateralis (per animal in total 300 mcl) in test "Forced swimming with load" in 3 months after introduction of AAV9-DYSF-DV.
EFFECT: invention can be used to improve physical performance.
1 cl, 1 dwg, 3 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF MYODYSTROPHY CORRECTION USING ADENO-ASSOCIATED VIRAL VECTOR IN EXPERIMENT | 2022 |
|
RU2821544C1 |
METHOD FOR CORRECTING MUSCULAR DYSTROPHY USING PLASMID DNA IN DYSFERLIN-DEFICIENT MICE | 2022 |
|
RU2805357C1 |
USING VECTOR FOR REDUCING IMMUNE RESPONSE IN VIRAL DELIVERY OF AIPL1 | 2023 |
|
RU2818342C1 |
PREPARATION FOR STIMULATING REGENERATION AND NEUROPROTECTION OF NERVE TISSUE AND METHOD OF USING SAME | 2023 |
|
RU2828544C1 |
NUCLEIC ACID DESIGNED TO REDUCE MAMMALIAN BODY WEIGHT, EXPRESSION VECTOR FOR EXPRESSION IN MAMMALIAN CELLS, METHOD FOR ITS DELIVERY AND METHOD FOR REDUCING MAMMALIAN BODY WEIGHT | 2023 |
|
RU2810191C1 |
METHOD OF TREATING LAMELLAR ICHTHYOSIS USING A RECOMBINANT ADENO-ASSOCIATED VIRUS BASED ON A GENETIC CONSTRUCT CODING A NUCLEOTIDE SEQUENCE OF A TRANSGLUTAMINASE 1 GENE | 2023 |
|
RU2821567C1 |
DRUG FOR THE TREATMENT OF METACHROMATIC LEUKODYSTROPHY AND A METHOD FOR ITS TREATMENT | 2021 |
|
RU2769577C1 |
ADENO-ASSOCIATED VIRAL VECTORS FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSIS TYPE IV A | 2019 |
|
RU2794960C2 |
CODON-OPTIMISED HAIPL1-ENCODING NUCLEOTIDE SEQUENCE AND EXPRESSION VECTOR CONTAINING SAID SEQUENCE | 2021 |
|
RU2785621C1 |
EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS CARRYING RECOMBINANT ANTIBODY GENES AND ITS USE FOR PREVENTION OF DISEASES CAUSED BY INFLUENZA A VIRUS AND SARS-CoV-2 VIRUS | 2023 |
|
RU2817792C1 |
Authors
Dates
2024-10-21—Published
2023-12-25—Filed